[Treatment of mycobacteriosis].
At present the increased incidence of infections with mycobacteria other than tuberculosis and leprae bacilli seems to be correlated with several causes: improved diagnostic techniques, prolonged life expectancy, immunodepression. Rational chemotherapy depends upon the identification of the etiologic mycobacterium and the determination of its drug susceptibility. Besides the "classic" treatment with 3 or 4 antituberculous and, sometimes, nonantituberculous chemotherapics, clinical trials are in progress to assess the effectiveness of new molecules: rifamycin derivatives, fluorinated quinolones, anti-lepromatous drugs, and the latest macrolides. Yet at present, national and international data do not permit to define a standard treatment for every mycobacteriosis; in fact, the drug resistance is high and varies not only between different strains but also within the same strain; moreover, there are discrepancies between in vitro and in vivo results. When possible, appropriated surgery for circumscribed disease is recommended.
Covi
M
M
Velluti
G
G
Bisetti
A
A
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000995:Antitubercular Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D009164:Mycobacterium Infections / Q000188:drug therapy*; D009165:Mycobacterium Infections, Nontuberculous / Q000150:complications / Q000188:drug therapy*; D015270:Mycobacterium avium-intracellulare Infection / Q000150:complications / Q000188:drug therapy
D000995:Antitubercular Agents
Terapia delle micobatteriosi.